Sector ratings Protagonist Therapeutics, Inc.

Equities

Delayed Nasdaq Other stock markets 16:00:00 2026-01-16 EST			5-day change	1st Jan Change
81.99 ^USD	-3.26%		+2.21%	-6.13%

01-13	Protagonist Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 08:15 AM
01-05	Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera	CI

Sector:

Location:

X axis:

Main competitors

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
PROTAGONIST THERAPEUTICS, INC.	5.13B		BB			-
LONZA GROUP AG	48.93B		AAA
SEAGEN INC.	43.15B	-	-	-	-	-	-	-
IQVIA HOLDINGS INC.	40.48B		AAA
BEONE MEDICINES AG	37.42B		-
CELLTRION, INC.	31.03B		A
REVOLUTION MEDICINES, INC.	23.25B	-	B	-		-
IMMUNOMEDICS, INC.	20.32B	-	-	-	-	-	-	-
MEDPACE HOLDINGS, INC.	17.21B		BBB
PPD, INC.	16.61B	-	-	-	-	-	-	-
EUROFINS SCIENTIFIC SE	14.78B		AA
ICON PUBLIC LIMITED COMPANY	13.94B		AA
REGENCELL BIOSCIENCE HOLDINGS LIMITED	13.56B	-	-	-	-	-	-	-
ASCENDIS PHARMA A/S	12.63B	-	-	-		-
TEMPUS AI, INC.	12.51B	-	A	-		-
IONIS PHARMACEUTICALS, INC.	12.36B	-	A	-		-
PRA HEALTH SCIENCES, INC.	10.96B	-	-	-	-	-	-	-
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	10.81B		A
BIO-TECHNE CORPORATION	10.7B		A
QIAGEN N.V.	9.8B		AAA
Average	20.28B		AA
Weighted average by Cap.			AA